Loading...
•
Mar 31, 2023
Disc Medicine Q1 2023 Earnings Report
Reported financial results for the first quarter ending March 31, 2023, and provided a business update.
Key Takeaways
Disc Medicine reported its Q1 2023 financial results, highlighting ongoing clinical studies for bitopertin and DISC-0974, in-licensing of anti-TMPRSS6 monoclonal antibodies, and a completed $62.5 million financing. The company's cash and cash equivalents were $236.4 million as of March 31, 2023, expected to fund operations into 2025.
Continued enrollment in Phase 2 clinical studies for bitopertin (BEACON and AURORA), with topline data expected by the end of 2023.
Ongoing Phase 1b/2 studies of DISC-0974 in patients with anemia of chronic kidney disease and myelofibrosis, with interim data expected by the end of 2023.
In-licensed anti-TMPRSS6 monoclonal antibodies from Mabwell Therapeutics, with a Phase 1 trial expected to start in the second half of 2023.
Completed a $62.5 million financing led by Bain Capital Life Sciences.